Schizophrenia Market to Gain Momentum During the Forecast Period (2026-2036), with Growing Pipeline of Novel and Long-Acting Therapies | DelveInsight

Olanzapine LAIPositive

AI Analysis

Summary

Market analysis predicts growth in the schizophrenia market through 2036, driven by rising disease prevalence and an expanding pipeline including Teva Pharmaceutical and MedinCell's Olanzapine LAI (TEV-44749/mdc-TJK).

Importance:3/10

Sentiment:

0.30

schizophrenialong-acting therapymarket growthpipelinenovel treatments

Related Companies

$TEVA $MEDCL.PA $RPRX

Read the original article

Published by PR Newswire Pharma on October 7, 2026 2:31 PM

Read Original